e-learning
resources
Milan 2017
Tuesday, 12.09.2017
Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Systemic inflamation and prognosis in lung cancer stage I-II
F. Verdu Rivera (Spain)
Source:
International Congress 2017 – Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Session:
Lung cancer: important scientific reports from endoscopists and thoracic surgeons
Session type:
Thematic Poster
Number:
4285
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Verdu Rivera (Spain). Systemic inflamation and prognosis in lung cancer stage I-II. 4285
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Related content which might interest you:
Treatment of non-microcelular lung cancer in its advanced stage
Source: Annual Congress 2008 - Treatment of thoracic tumours
Year: 2008
Effect of cardiovascular comorbidities on the survival patients with stage I and II non-small-cell lung cancer
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
Management of locally advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 260–270
Year: 2009
Prognostic factors in patients with resected pathologic stage I and II nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2002; 20: Suppl. 38, 269s
Year: 2002
Age and stage at presentation in lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005
Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010
Systemic treatment of advanced NSCLC
Source: Annual Congress 2007 - PG7 - Thoracic oncology: nonsmall cell lung cancer
Year: 2007
Current neoadjuvant/adjuvant treatment for advanced stage lung cancer
Source: International Congress 2014 – PG19 Surgery for advanced stage lung cancer
Year: 2014
Disease relapse in surgically and conservatively treated patients with stage I-II of non-small cell lung cancer
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010
Management of stage I and II nonsmall cell lung cancer
Source: Eur Respir J 2017; 49(1): 1600764; DOI: 10.1183/13993003.00764-2016
Year: 2017
Treatment of early (stage I/II) non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
Clinicopathologic features of patients with non-small cell lung cancer and chronic obstructive pulmonary disease undergoing lung cancer surgery
Source: Virtual Congress 2020 – Localised non-small cell lung cancer
Year: 2020
Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019
Prognostic factors in resected pathological N1-stage II nonsmall cell lung cancer
Source: Eur Respir J 2013; 41: 649-655
Year: 2013
A retrospective analysis of risk factors for Durvalumab related interstitial lung disease after chemoradiotherapy in Stage III NSCLC
Source: Virtual Congress 2020 – Localised non-small cell lung cancer
Year: 2020
Comparative evaluation of resectability, postoperative morbidity and mediastinal downstaging after cisplatin-based chemoinduction versus radiochemoinduction for stage III non-small cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 214s
Year: 2003
Surfactant protein-D level as a predictor of prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer
Source: International Congress 2016 – Orphan diseases I
Year: 2016
Survival of patients operated for stage I non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Carboplatin-paclitaxel alone or with bevacizumab in stage III-IV lung adenocarcinoma
Source: Annual Congress 2011 - Treatment of lung cancer
Year: 2011
A study on chemotherapy induced interstitial lung disease in patients with unresectable non-small cell lung cancer complicated by combined pulmonary fibrosis and emphysema
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept